Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05970731 · ClinicalTrials.gov registry record · Phase 2
Directed Topical Drug Delivery for Treatment for PASC Hyposmia
A Phase 2 study of Post Acute Sequelae Covid-19 Hyposmia, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05970731: Completed Phase 2 study of Post Acute Sequelae Covid-19 Hyposmia, sponsored by Duke University.
NCT05970731 is a Phase 2 study of Post Acute Sequelae Covid-19 Hyposmia that has completed, run by Duke University. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05970731, a Phase 2 study of Post Acute Sequelae Covid-19 Hyposmia, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy of topical intranasal treatment of beclomethasone vs. placebo for improved olfactory function.
Primary Outcome
The SIT has a score range of 0 to 40, where a higher score reflects better olfactory function. MCID is defined at a 4 point increase.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Beclomethasone
- DEVICE Microsponge
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-09-05 |
| Est. Completion | 2024-10-07 |
| Phase | Phase 2 |
What the finished NCT05970731 record still lists
NCT05970731 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Post Acute Sequelae Covid-19 Hyposmia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05970731 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05970731 about?
NCT05970731 is a clinical study titled "Directed Topical Drug Delivery for Treatment for PASC Hyposmia". This is a phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy of topical intranasal treatment of beclomethasone vs. placebo for improved olfactory function.
What is the current status of trial NCT05970731?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2023-09-05. Estimated completion is 2024-10-07.
What conditions does trial NCT05970731 study?
This clinical trial studies the following conditions: Post Acute Sequelae Covid-19 Hyposmia.
What interventions are being tested in trial NCT05970731?
The interventions under investigation include: Placebo (OTHER), Beclomethasone (DRUG), Microsponge (DEVICE).
Who is sponsoring clinical trial NCT05970731?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05970731 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05970731's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI